Is a 5 mg dose of melatonin effective for improving sleep onset latency and overall sleep quality in adults?

Efficacy of 5 mg Melatonin for Sleep

A 5 mg dose of melatonin shows no clinically meaningful benefit for sleep in adults; the evidence demonstrates that 2 mg prolonged-release melatonin is the optimal dose, with 5 mg specifically studied and found ineffective for improving sleep latency, total sleep time, or sleep quality. 1

Evidence Against 5 mg Dosing

• The Baskett study directly evaluated 5 mg melatonin in elderly adults with sleep maintenance problems and found no improvement in sleep latency, total sleep time, sleep efficiency, or quality of sleep compared to placebo. 1
• The American Academy of Sleep Medicine clinical practice guideline reviewed multiple doses and found that higher doses do not produce better outcomes; in fact, lower doses (0.1–0.3 mg) may be more effective than higher doses due to potential receptor desensitization. 1, 2

Optimal Dosing Strategy

• Start with 1–2 mg of prolonged-release melatonin taken 1–2 hours before bedtime; this dose has the strongest evidence base in adults aged ≥55 years, producing a clinically meaningful reduction in sleep latency of approximately 19 minutes. 3, 4
• In elderly patients (65–80 years), 2 mg prolonged-release melatonin reduces sleep latency by 19.1 minutes at 3 weeks and 25.9 minutes at 19 weeks, compared to placebo reductions of only 1.7 and 8.3 minutes respectively. 3
• If no improvement occurs after 3 weeks on 2 mg, the dose may be increased to 3 mg nightly, with 5 mg representing an upper limit that lacks supporting efficacy data. 3

Overall Quality of Evidence and Guideline Position

• The American Academy of Sleep Medicine issues a weak recommendation against routine melatonin for chronic insomnia, citing very low quality evidence due to publication bias, heterogeneity, and imprecision. 1, 3
• The meta-analysis of quality of sleep showed only a small, clinically insignificant improvement (SMD +0.21; CI: -0.36 to +0.77), with very low quality evidence. 1
• Despite the weak evidence, melatonin demonstrates a favorable safety profile with adverse event rates comparable to placebo across all studied doses and durations. 1

Clinical Context and Alternatives

• Cognitive-Behavioral Therapy for Insomnia (CBT-I) should be first-line treatment for chronic insomnia, either before or alongside any pharmacologic agent, as it yields superior long-term outcomes. 3
• If melatonin proves ineffective, low-dose doxepin (3–6 mg) is the preferred alternative for sleep-maintenance insomnia, showing a 22–23 minute reduction in wake after sleep onset with minimal anticholinergic effects. 3
• Ramelteon 8 mg (a prescription melatonin-receptor agonist) is appropriate for sleep-onset insomnia and carries no abuse potential. 3

Key Implementation Points

• Use prolonged-release formulations rather than immediate-release; sustained-release preparations are more effective for the sleep-maintenance pattern common in adults. 1, 2
• Administer 1–2 hours before bedtime, not at bedtime itself, to optimally synchronize circadian rhythms. 3, 2
• The most compelling evidence for melatonin efficacy exists in elderly patients with documented low melatonin levels or those chronically using benzodiazepines. 5
• No clinically significant drug-drug interactions have been identified with common medications such as SSRIs, beta-blockers, or other CNS-active agents, though monitoring for additive sedation is prudent. 3